Pyxis Oncology (PYXS) Cash & Current Investments (2020 - 2025)
Pyxis Oncology (PYXS) reported Cash & Current Investments of $16.9 million for Q4 2025, down 19.34% year-over-year from $20.9 million in Q4 2024, and up 62.58% on a QoQ basis from $10.4 million in Q3 2025.
Pyxis Oncology (PYXS) has 6 years of Cash & Current Investments data on file, last reported at $16.9 million in Q4 2025.
- Quarterly Cash & Current Investments fell 19.34% year-over-year to $16.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.9 million (down 19.34% YoY) and the FY2025 annual result came in at $16.9 million, down 19.34% from the prior year.
- Cash & Current Investments grew to $16.9 million in Q4 2025 per PYXS's latest filing, from $10.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $276.2 million in Q4 2021 and bottomed at $10.4 million in Q3 2025.
- The 5-year median for Cash & Current Investments is $126.1 million (2023), against an average of $116.0 million.
- The widest annual swing landed in 2021, when Cash & Current Investments jumped 1086.88%; it then sank 89.83% in 2024.
- Tracing PYXS's Cash & Current Investments over 5 years: stood at $276.2 million in 2021, then plunged by 34.55% to $180.8 million in 2022, then tumbled by 34.0% to $119.3 million in 2023, then slumped by 82.44% to $20.9 million in 2024, then decreased by 19.34% to $16.9 million in 2025.
- Per Business Quant, the three latest PYXS Cash & Current Investments figures stand at $16.9 million (Q4 2025), $10.4 million (Q3 2025), and $88.9 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 901.90 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 8.75 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | 18.44 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Pyxis Oncology | 120.87 Mn | 103.97 Mn | 8.65 Mn | 16.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.89 Mn |
| Sep 30, 2025 | 10.39 Mn |
| Jun 30, 2025 | 88.94 Mn |
| Mar 31, 2025 | 105.43 Mn |
| Dec 31, 2024 | 20.95 Mn |
| Sep 30, 2024 | 13.53 Mn |
| Jun 30, 2024 | 26.55 Mn |
| Mar 31, 2024 | 157.03 Mn |
| Dec 31, 2023 | 119.30 Mn |
| Sep 30, 2023 | 132.97 Mn |
| Jun 30, 2023 | 27.37 Mn |
| Mar 31, 2023 | 54.53 Mn |
| Dec 31, 2022 | 180.77 Mn |
| Sep 30, 2022 | 200.01 Mn |
| Jun 30, 2022 | 224.83 Mn |
| Mar 31, 2022 | 248.56 Mn |
| Dec 31, 2021 | 276.21 Mn |
| Sep 30, 2021 | 133.48 Mn |
| Jun 30, 2021 | 142.47 Mn |
| Mar 31, 2021 | 140.66 Mn |
| Sep 30, 2020 | 11.25 Mn |